Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05340673 · ClinicalTrials.gov registry record · Phase 1
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
A Phase 1 study of Invasive Breast Carcinoma and Breast Ductal Carcinoma In Situ, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 208
- Enrollment target
- 1
- Study location
NCT05340673 is a Phase 1 study of Invasive Breast Carcinoma and Breast Ductal Carcinoma In Situ that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 208 participants, below the 480-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05340673, a Phase 1 study of Invasive Breast Carcinoma and Breast Ductal Carcinoma In Situ, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 208 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial compares two supplemental topical agents (Aquaphor and Miaderm) for the treatment of acute radiation dermatitis in patients with breast cancer undergoing radiation therapy. Radiation dermatitis is a radiation-induced skin reaction which can cause itching, swelling, pain, and general discomfort. Aquaphor is a commonly available, inexpensive, petrolatum-based multi-purpose ointment designed to protect and sooth extremely dry skin, chapped lips, cracked hands and feet, minor cuts and burns, and many other skin irritations. Miaderm is a water-based cream and contains ingredients like calendula, hyaluronate, and aloe vera which may help reduce occurrence and severity of radiation dermatitis. Both are commonly recommended and used by breast cancer patients undergoing external beam radiation therapy (EBRT). However, it is not known whether one is better than the other in treating or preventing radiation dermatitis.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- DRUG Agent Affecting Integumentary System
- OTHER Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05340673
The ClinicalTrials.gov registry entry for NCT05340673 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 480-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (57% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05340673 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05340673 about?
NCT05340673 is a clinical study titled "Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer". This clinical trial compares two supplemental topical agents (Aquaphor and Miaderm) for the treatment of acute radiation dermatitis in patients with breast cancer undergoing radiation therapy. Radiation dermatitis is a radiation-induced skin reaction which can cause itching, swelling, pain, and gene...
What is the current status of trial NCT05340673?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 208 participants. The study started on 2022-06-21. Estimated completion is 2026-12-15.
What conditions does trial NCT05340673 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Breast Ductal Carcinoma In Situ.
What interventions are being tested in trial NCT05340673?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Agent Affecting Integumentary System (DRUG), Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment (OTHER).
Who is sponsoring clinical trial NCT05340673?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05340673 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
RECRUITING · Phase 1
-
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
RECRUITING · Phase 1
-
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
RECRUITING · Phase 1
-
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Breast Cancer Survivorship Biorepository
RECRUITING
-
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
RECRUITING
Explore more on PlainTrial
Invasive Breast Carcinoma
All registered trials for this condition
Breast Ductal Carcinoma In Situ
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.